Safety of cenobamate for Japanese adults with partial seizures
Treatments studied
Part of Brain & nervous system clinical trials.
This trial studies the safety of cenobamate for Japanese people who have partial onset seizures and have already finished a previous study of the same drug. It helps doctors learn more about long-term safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the earlier study called YKP3089C035.
- You must not have stopped that earlier study for any reason.
- You must not have any major new health problems that could make the drug unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine (ONO-2017) for people with a type of epilepsy that causes whole-body seizures. It looks at whether adding this drug to your current seizure medicines can reduce how often those seizures happen.
This study looks at how well cenobamate works when added to other seizure medications for adults with focal epilepsy. It uses real-world data from medical records to see how people respond to treatment.
This study looks at how cenobamate (a medication for seizures) affects healthcare use, like hospital visits or emergency room trips, in people with epilepsy whose seizures were not well-controlled by 2 to 5 other medicines. It is a real-world study, meaning it uses medical records to understand the impact.
This trial tests if a new seizure medicine called cenobamate can help control frequent or ongoing seizures in intensive care unit patients who are already on other seizure medications.
This trial tests whether a new seizure medicine (cenobamate) helps people whose seizures are caused by an overactive immune system. You would stay on your current treatments and add cenobamate to see if it reduces seizures.
This study tests a new seizure medication called ONO-2017 in Japanese children and teenagers (ages 2–17) who have a specific type of seizure called POS that hasn't been controlled by current medicines. The goal is to see if this new drug is safe and helps reduce these seizures.
Hear when a new Epilepsies, Partial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.